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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the 
use of omega-3 polyunsaturated fatty acids (PUFA) as adjunctive therapy is effective in reducing 
symptom severity in adult schizophrenia patients. 
 
STUDY DESIGN: A selective review of three peer-reviewed, double-blind, randomized, 
placebo-controlled trials published between the years of 2008 and 2016.  
 
DATA SOURCES: All three randomized control trials were published in English and were 
selected from peer-reviewed journals via EmBase and PubMed based on relevance to the clinical 
question posed above and that the outcomes measured in the studies mattered to patients, or were 
“patient oriented.” 
 
OUTCOMES MEASURED: Outcomes of changes in schizophrenia symptom severity were 
measured by comparing Positive and Negative Symptom Scale (PANSS) scores before and after 
treatment with either antipsychotic plus placebo or antipsychotic plus omega-3 PUFA.  
 
RESULTS: Studies performed by Manteghiy, et. al. and Bentsen, et. al. revealed no statistically 
significant improvements in PANSS scores before and after treatment with antipsychotic plus 
omega-3 PUFA. The study performed by Pawelczyk, et. al. revealed statistically significant 
improvement in PANSS scores before and after treatment with antipsychotic plus omega-3 
PUFA.  
 
CONCLUSIONS: Based on the selective review of the studies included in this paper, evidence 
is still unclear as to whether or not the use of omega-3 PUFAs as adjunctive therapy is effective 
in reducing symptom severity in adult schizophrenia patients. Further research into the topic 
must be conducted in order to gather more evidence, as only a limited number of clinical trials all 
with small sample sizes observed over a short time frame have been performed throughout the 
last 10 years.  
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INTRODUCTION 
 Schizophrenia is the most common psychotic illness diagnosed in the U.S., affecting 7 in 
1000 people throughout their lifetime.1 Although this may seem like a modest prevalence, being 
familiar with the treatment available for schizophrenia is relevant to all fields of medicine and 
providers throughout all specialties, since about 50-90% of people with mental illness additionally 
need treatment for one or more chronic medical illnesses.1 The estimated cost of treating patients 
with schizophrenia in the U.S. was estimated to total $155.7 billion in 2013. This includes not only 
direct healthcare costs but also societal costs such as caregiving and unemployment.2  Throughout 
2009-2011, schizophrenia is estimated to have produced 382,000 emergency department visits 
yearly in the U.S., which includes adults aged 18-64; this totals to about 20.1 visits per every 
10,000 adults in the U.S.3  Thus, it is evident that this disease affects not only the healthcare system, 
but society as a whole.  
Schizophrenia is a chronic psychiatric illness with onset in early adulthood. The disease 
has periods of inactivity through its course as well as periods of active disease defined by episodes 
of psychosis. When a patient is actively going through psychosis, this period is characterized by 
the patient’s inability to distinguish between reality and unreality. The psychotic symptoms of 
schizophrenia are categorized into “positive” and “negative” symptoms. Positive symptoms 
include hallucinations, delusions, and bizarre behavior. Negative symptoms include flat affect, 
anhedonia, apathy, and decrease speech.4   
 The exact cause of schizophrenia remains unknown. However, since antipsychotic 
medication, the staple of maintenance treatment in schizophrenia, affects dopamine and serotonin 
receptors in the brain, it is known that these are the main neurotransmitters involved in the 
mechanism of action and process of the disease. Both first-generation, or “typical”, antipsychotics 
and second-generation, or “atypical”, antipsychotics are prescribed to patients with schizophrenia 
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as maintenance therapy in order to reduce the frequency and severity at which patients experience 
psychotic symptoms. Typical antipsychotics include chlorpromazine, perphenazine, and 
haloperidol while atypical antipsychotics include clozapine, risperidone, olanzapine, quetiapine, 
ziprasidone, and aripiprazole.1  
While the negative symptoms of this disease are arguably the most debilitating, 
antipsychotic medications are only proven to target the improvement of positive symptoms of 
psychosis through their chemical mechanism of action. Arguably, many claim that by controlling 
the frequency and severity of positive symptoms, antipsychotics simultaneously aid in decreasing 
the severity of negative symptoms, as well. However, evidence-based research on pharmacologic 
treatment directly targeting the reduction in severity of negative symptoms still remains elusive, 
as does a cure for the disease.  
The treatment options discussed above are all crucial in maintenance treatment of 
schizophrenia, but the elusive nature of a cure requires research into alternative, adjunctive 
treatment. It is important to assess the efficacy of the use of alternative medicine in symptom 
improvement, especially since many antipsychotics have intolerable side effects. Omega-3 
polyunsaturated fatty acids (PUFAs) have been found to be one alternative medicine option to 
have positive effects on patients with schizophrenia. Research into this option of adjunctive 
therapy has been ongoing since the 1980s, when it was discovered that omega-3 fatty acid 
concentrations were low in schizophrenia patients. The thought behind providing supplementation 
of these compounds to patients is that they promote cellular wall formation, which decreases 
neuronal destruction and in turn the active symptomatology of this chronic disease.5 This paper 
goes on to evaluate three double-blind, randomized, placebo-controlled trials comparing the 
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efficacy of omega-3 PUFAs as adjunctive therapy in reducing symptom severity for adults with 
schizophrenia. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not the use of 
omega-3 polyunsaturated fatty acids (PUFAs) as adjunctive therapy is effective in reducing 
symptom severity in adult schizophrenia patients. 
METHODS 
 Three double-blind, randomized, placebo-controlled trials were chosen for review. The 
patient population selected for review included patients over the age of 18 years old presenting 
with first-episode schizophrenia. The interventions whose efficacy were assessed included omega-
3 PUFAs as adjunctive treatment for patients that were also prescribed antipsychotic therapy. The 
results of control groups receiving antipsychotic therapy in conjunction with a placebo were 
compared to results of experimental groups receiving antipsychotic therapy in conjunction with 
omega-3 PUFAs. For purposes of this paper, outcomes measured focused on the reduction of 
symptom severity in adult schizophrenia patients as measured by the patients’ Positive and 
Negative Symptom Scale (PANSS) scores before and after treatment.  
 All articles being reviewed were selected from peer-reviewed journals via EmBase and 
PubMed based on relevance to the clinical question posed above and that the outcomes measured 
in the studies mattered to patients, or were “patient oriented.”  The three studies were all published 
in English between the years of 2008 and 2016. Keywords used to research the topic were “omega-
3 fatty acids” and “schizophrenia”. Inclusion criteria for the studies selected were that they were 
double-blind, randomized, placebo-controlled trials published after the year 2008. Exclusion 
criteria included studies focused on patients under the age of 18 years old previously diagnosed 
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with schizophrenia being treated solely with antipsychotics. Detailed inclusion and exclusion 
criteria as well as demographics of patient populations of each individual study are outlined in 
Table 1 below. The statistics reported in the studies and utilized for review include p-values. 
Table 1 – Demographics & Characteristics of Included Studies 
Study Type # 
pts 
Age 
(years) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Manteghiy5 
(2008) 
RCT 85 Active 
treatment 
= 37.38 ± 
6.2  
 
Placebo 
= 39.03 ± 
7.12  
Diagnosis of 
schizophrenia 
confirmed by 2 
psychiatrists 
using DSM-4 
criteria  
Use of depot 
antipsychotic 
medication; 
substance 
dependency; 
medical 
illness during 
2 weeks prior 
to start of 
study 
0 Active 
treatment: 
yellow pearls 
of 2000 mg 
fish oil, 360 
mg EPA, and 
240 mg DHA  
vs. placebo 
similar in 
appearance 
Bentsen6 
(2013) 
RCT 97 18-39 Schizophrenia, 
schizo-
affective 
disorder, or 
schizo-
phreniform 
disorder; 
admitted to a 
Norwegian 
psychiatric 
department 
within the last 
21 days and 
prescribed 
antipsychotics 
Substance 
dependence; 
allergy to trial 
agents; 
current 
warfarin use; 
indicators of 
impaired 
hemostasis 
24 Active 
treatment: 2 
capsules 
twice a day 
of 500 mg 
EPA plus 2 
capsules 
twice a day 
of 500 mg 
paraffin oil 
Placebo: 4 
capsules 
twice a day 
of 500 mg 
paraffin oil 
Pawełczyk7 
(2016) 
RCT 71 16-35 Aged 16-35 
and diagnosed 
with first-
episode 
schizophrenia 
according to 
the ICD-10 
> 2 years 
since positive 
symptom 
onset; use of 
anticoagulant; 
omega-3 fatty 
acid within 8 
weeks; mania, 
drug-induced 
psychosis, 
organic 
disorders, or 
5 Active 
treatment: 4 
yellow gel 
capsules 
containing 
0.33 g of 
EPA and 
0.22 g of 
DHA each 
Placebo: 4 
yellow gel 
capsules 
Goenaga, Omega-3 PUFAs and Schizophrenia 5 
 
intellectual 
disability; 
unstable 
medical 
condition 
filled with 
olive oil 
 
OUTCOMES MEASURED 
 The primary outcomes measured for purposes of this selective EBM review were the 
reduction of symptom severity in adult schizophrenia patients as measured by changes in Positive 
and Negative Symptoms Severity (PANSS) scores before and after treatment with either 
antipsychotic in conjunction with placebo (control group) or antipsychotic in conjunction with 
omega-3 PUFA (experimental group). Total PANSS scores used for purposes of comparison were 
calculated by the researcher by averaging the PANSS scores in each study that fell under the 
categories of “positive symptoms”, “negative symptoms”, and “general/general 
psychopathology”. The PANSS scores from the beginning of each study and the end of each study 
were compared, and the mean change from baseline as well as the percent change in baseline 
between control and experimental groups was compared to evaluate efficacy of the interventions 
in reference to the p-values indicated in each study. 
RESULTS 
 Manteghiy, et. al. conducted a randomized control trial on 85 subjects: 42 subjects received 
the antipsychotic risperidone 2-8 mg by mouth in one daily dose in conjunction with an omega-3 
PUFA which came in the form of a yellow pearl consisting of 2000 mg fish oil, 360 mg EPA, and 
240 mg DHA while 43 subjects received the same antipsychotic but with a placebo pill similar in 
appearance to the omega-3 PUFA.5 Patient demographics as well as inclusion and exclusion 
criteria were similar for each group, and are detailed in Table 1 above. Both groups received the 
assigned interventions daily, and PANSS scores were recorded at weeks 0, 3, and 6.  
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Table 2 – PANSS Scores in Placebo and Omega-3 PUFA Groups5 
 Week 0 Week 6 Mean 
Change 
from 
Baseline 
% 
Change 
from 
Baseline 
p-value 
Risperidone + placebo  48.927 38.890 -10.037 20.514 0.001 
Risperidone + Omega-3 PUFA  49.833 38.457 -11.376 22.828 0.002 
 
 Comparison of the percent changes from baseline between the placebo and experimental 
groups depicted in Table 2 above revealed no statistically significant changes in PANSS scores 
from week 0 to week 6 of the study, as the researchers of this study defined a p-value greater than  
0.1 as statistically significant. This indicates that although 2.314% more subjects receiving 
risperidone in conjunction with the omega-3 PUFA reported improvement in their PANSS scores 
after treatment, this outcome is more likely attributed to chance and is therefore not reliable in 
assessing the true efficacy of the interventions. 
 Bentsen, et. al. conducted a randomized control trial on 104 subjects aged 18-39 years old 
in which they assessed the efficacy of antipsychotic in conjunction with placebo omega-3 PUFA 
and placebo vitamins versus antipsychotic in conjunction with placebo omega-3 PUFA and active 
vitamins, antipsychotic in conjunction with active omega-3 PUFA and placebo vitamins, or 
antipsychotic in conjunction with active omega-3 PUFA and active vitamins.6 However, for the 
purposes of this paper, the outcomes of only 58 subjects were assessed: the control group consisted 
of 25 subjects receiving antipsychotic in conjunction with placebo omega-3 PUFA and placebo 
vitamins while the experimental group consisted of 33 subjects receiving antipsychotic in 
conjunction with active omega-3 PUFA and placebo vitamins. The antipsychotics varied among 
patients, as they were prescribed at the choice of the researching therapist. The control group 
received their prescribed antipsychotic along with four capsules twice a day of 500 mg of paraffin 
oil. The experimental group received their prescribed antipsychotic along with two capsules twice 
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a day of 500 mg of active EPA and two capsules twice a day of 500 mg of paraffin oil. Patient 
demographics as well as inclusion and exclusion criteria were similar for each group, and are 
detailed in Table 1 above. Both groups received the assigned interventions daily, and PANSS 
scores were recorded at weeks 0, 4, 8, and 16. 
Table 3 – PANSS Scores in Placebo and Omega-3 PUFA Groups6 
 Week 
0 
Week 
16 
Mean 
Change from 
Baseline 
% 
Change 
from 
Baseline 
p-value 
Antipsychotic + placebo 80.8 58.7 -22.1 27.351 0.0001  
Antipsychotic + Omega-3 PUFA  80.8 68.8 -12.0 14.851 0.248 
 
Comparison of the percent changes from baseline between the placebo and experimental 
groups depicted in Table 3 above revealed no statistically significant changes in PANSS scores 
from week 0 to week 16 of the study in the experimental group, as the researchers of this study 
defined a p-value less than  0.05 as statistically significant. However, the changes in PANSS scores 
for the control group were found to be statistically significant. This indicates that the changes in 
the experimental group were likely attributed to chance and are therefore not reliable in assessing 
the true efficacy of the interventions. Further, 12.5% more subjects receiving antipsychotic in 
conjunction with placebo reported improvement in their PANSS scores after treatment, which also 
shows that this study did not show any positive relationship between the addition of omega-3 
PUFAs in the treatment regimen of patients with schizophrenia and improvement in PANSS 
scores. 
Pawelczyk, et. al. conducted a randomized control trial on 71 subjects aged 16-35 years 
old. The antipsychotics varied among patients, as they were prescribed and titrated according to 
the Polish standards of pharmacotherapy of mental disorders; however, all antipsychotics were 
dosed similarly by converting their doses into chlorpromazine equivalents. 36 patients in the 
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experimental group received antipsychotic in conjunction with four yellow gel capsules containing 
0.33 g of EPA and 0.22 g of DHA each while 35 patients in the placebo group received 
antipsychotic in conjunction with four yellow gel capsules filled with olive oil.7 Patient 
demographics as well as inclusion and exclusion criteria were similar for each group, and are 
detailed in Table 1 above. Both groups received the assigned interventions daily, and PANSS 
scores were recorded at weeks 0, 2, 4, 6, 8, and 26.  
Table 4  – PANSS Scores in Placebo and Omega-3 PUFA Groups7 
 Week 
0 
Week 
26 
Mean 
Change 
from 
Baseline 
% 
Change 
from 
Baseline 
p-value 
Chlorpromazine + placebo 96.80 82.38 -14.42 14.90 0.016 
Chlorpromazine + Omega-3 PUFA  98.40 79.13 -19.27 19.58 0.017 
 
Comparison of the percent changes from baseline between the placebo and experimental 
groups depicted in Table 4 above revealed statistically significant changes in PANSS scores from 
week 0 to week 26 of the study in the experimental group, as the researchers of this study defined 
a p-value less than 0.05 as statistically significant. This indicates that the changes in the 
experimental group are reliable in assessing the true efficacy of the interventions. Further, 4.68% 
more subjects receiving chlorpromazine-equivalent antipsychotic in conjunction with omega-3 
PUFA reported improvement in their PANSS scores after treatment, which also shows that this 
study did find evidence in support of a positive relationship between the addition of omega-3 
PUFAs in the treatment regimen of patients with schizophrenia and improvement in PANSS 
scores. 
Although all patients in these studies were being treated with antipsychotics, which have 
marked adverse reactions including extrapyramidal symptoms (EPS), tardive dyskinesia, diarrhea, 
constipation, weight changes, and changes in libido, the articles do not comment much further on 
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how many subjects in their trials experienced these reactions. This was controlled by tracking 
compliance in every subject throughout the entire duration of all studies. Further, more 
commentary on the adverse reactions was not necessary, as the outcomes being measured focused 
on omega-3 PUFA supplementation, which has no known or documented serious adverse reactions 
in comparison to the antipsychotics.  
DISCUSSION  
 There were several limitations to the studies selected for review that must be discussed in 
order to gain a better understanding of the scope and limitation of the results derived from the 
research for this paper.  
First, the study conducted by Bentsen, et. al. included patients with diagnoses of psychotic 
disorders that were not only limited to schizophrenia, such as schizoaffective disorder and 
schizophreniform disorder. Since the other studies focused on patients with the sole diagnosis of 
schizophrenia, this could have greatly skewed the results explained in this paper. Further, although 
both  studies by Manteghiy, et. al. and Pawelczyk, et. al. focused only on patients with a diagnosis 
of schizophrenia, the definitions that were utilized varied. Manteghiy, et. al. defined schizophrenia 
according to DSM-4 criteria while Pawelczyk, et. al. utilized the definition of schizophrenia as 
outlined in ICD-10. The definitions are clearly similar, as the disease process remains the same, 
but these minor details should have been taken into account and controlled in order to have results 
that are more readily available for direct comparison. 
 Further, it must be addressed that although the question for this paper focuses on “adult 
schizophrenia patients,” the population for the study performed by Pawelczyk, et. al. included 
subjects aged 16-35 years old. The study does not go into detail outlining how many subjects were 
under the age of 18, which would be important to note for purposes of this review since the 
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population specified in the clinical question being posed specifies “adult” patients, which includes 
those over the age of 18 years old. The question also does not specify whether or not the patients 
being studied and treated are being managed in an inpatient setting or outpatient setting. Studies 
performed by Manteghiy, et. al. and Pawelczyk, et. al. focused on patients admitted to psychiatric 
departments in various hospitals for the first time that had never received treatment with 
antipsychotics before. On the other hand, Bentsen, et. al. focused on patients admitted to a 
psychiatric department in various hospitals for the first time within the past 21 days; thus, these 
patients could have been receiving a regimen of antipsychotics for longer than in the other studies. 
 Lastly,  all of the studies reviewed had small sample sizes and were conducted over 
relatively short periods of time. Adjusting these factors would provide more evidence to further 
look into the true efficacy of omega-3 PUFAs as adjunctive treatment in adult schizophrenia 
patients. 
CONCLUSIONS 
 Overall, the results of the studies in this systematic review provide no conclusive evidence 
as to whether or not the use of omega-3 PUFAs as adjunctive therapy is effective in reducing 
symptom severity in adult schizophrenia patients. Secondary to the limitations of each study and 
variables that are difficult to control, most namely the definitions of schizophrenia utilized for all 
subjects across all studies and the inclusion of patients with other psychotic disorders, it can be 
concluded that the current evidence provided on the topic is very limited.  Therefore, further 
studies with inclusion criteria that is more specific as well as studies that observe subjects through 
longer periods of time may be necessary to gain a better understanding  of the role of omega-3 
PUFAs, a very benign supplement with no serious known side effects, in the treatment of 
schizophrenia, a disease that affects millions.
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